Evogene | EVGN

Stock Price
403.20
Daily Change
-13.80 -3.31%
Monthly
-0.74%
Yearly
-64.60%
Q3 Forecast
414.08

Peers Price Chg Day Year Date
Evogene 403.20 -13.80 -3.31% -64.60% Sep/07
Hawkins 167.14 -1.55 -0.92% 44.42% Sep/05
Innospec 85.72 -0.14 -0.16% -19.58% Sep/05
Koppers 28.87 0.25 0.87% -21.16% Sep/05
Kronos Worldwide 6.20 0.08 1.31% -42.65% Sep/05
Materion 112.59 1.63 1.47% 8.60% Sep/05
Minerals Technologies 64.11 0.84 1.33% -10.81% Sep/05
Rayonier Advanced Materials 5.93 0.27 4.77% -20.51% Sep/05
Stepan 50.15 0.65 1.31% -30.58% Sep/05
Sensient Technologies 112.84 0.01 0.01% 52.30% Sep/05
Tronox 4.48 0.30 7.18% -63.78% Sep/05
CVR Partners 87.98 -0.48 -0.54% 30.98% Sep/05
Valhi 16.30 0.18 1.12% -40.75% Sep/05
WD-40 218.08 1.42 0.66% -16.58% Sep/05

Indexes Price Day Year Date
TA-125 3135 25.61 0.82% 53.64% Sep/07

Evogene traded at 403.00 this Sunday September 7th, decreasing 14.00 or 3.36 percent since the previous trading session. Looking back, over the last four weeks, Evogene lost 0.79 percent. Over the last 12 months, its price fell by 64.62 percent. Looking ahead, we forecast Evogene to be priced at 414.08 by the end of this quarter and at 405.45 in one year, according to Trading Economics global macro models projections and analysts expectations.

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.